EMA: Draft Quality Guidelines for Synthetic Peptides and Oligonucleotides
The European Medicines Agency (EMA) plans to establish clear quality guidelines for drug companies manufacturing synthetic peptides and oligonucleotides. This week, EMA published new concept papers, explaining current requirements on impurities testing, specifications and the control of DNA-reactive chemicals either partly or fully exclude synthetic peptides and oligonucleotides.
According to the agency, the proposed guidelines would address aspects of peptide and oligonucleotide manufacturing, characterisation, specification and analytical control “not covered in the Guideline on the Chemistry of Active Substances (EMA/454576/2016) and Chemistry of Active Substances for Veterinary Medicinal Products (EMA/CVMP/QWP/707366/2017).”
Source:
RAPS.org: Regulatory News
EMA: Concept Paper on Synthetic Peptides and Concept Paper on Synthetic Oligonucleotides
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
